Clinical Response Among Participants with Warts in the Phase 3 Trial, Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome
J Hum Immun (2025) 1 (CIS2025): CIS2025abstract.59.
Currently there are no citedby results. Try again later.
